- Home
- PR vs EXAS Comparison
PR vs EXAS Comparison
Compare PR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PR
- EXAS
- Stock Information
- Founded
- PR 2015
- EXAS 1995
- Country
- PR United States
- EXAS United States
- Employees
- PR N/A
- EXAS N/A
- Industry
- PR Oil & Gas Production
- EXAS Medical Specialities
- Sector
- PR Energy
- EXAS Health Care
- Exchange
- PR Nasdaq
- EXAS Nasdaq
- Market Cap
- PR 10.1B
- EXAS 10.5B
- IPO Year
- PR 2016
- EXAS N/A
- Fundamental
- Price
- PR $15.99
- EXAS $51.74
- Analyst Decision
- PR Strong Buy
- EXAS Strong Buy
- Analyst Count
- PR 17
- EXAS 16
- Target Price
- PR $19.06
- EXAS $72.80
- AVG Volume (30 Days)
- PR 7.5M
- EXAS 2.2M
- Earning Date
- PR 02-25-2025
- EXAS 02-19-2025
- Dividend Yield
- PR 2.19%
- EXAS N/A
- EPS Growth
- PR 85.31
- EXAS N/A
- EPS
- PR 1.65
- EXAS N/A
- Revenue
- PR $4,827,339,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- PR $66.20
- EXAS $11.81
- Revenue Next Year
- PR $6.55
- EXAS $11.52
- P/E Ratio
- PR $9.69
- EXAS N/A
- Revenue Growth
- PR 74.92
- EXAS 11.91
- 52 Week Low
- PR $12.59
- EXAS $40.62
- 52 Week High
- PR $18.28
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- PR 71.27
- EXAS 35.28
- Support Level
- PR $14.70
- EXAS $49.79
- Resistance Level
- PR $15.67
- EXAS $60.88
- Average True Range (ATR)
- PR 0.38
- EXAS 2.67
- MACD
- PR 0.17
- EXAS -0.59
- Stochastic Oscillator
- PR 98.25
- EXAS 17.58
About PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are primarily concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.